Biomarin Pharmaceutical price to sales ratio BMRN
Market value divided by revenue over the last twelve months, since 2011.
- Today, Nov 2, 2026
- 3.3×
- 10-year median
- 8.2×
- Against its 10-year history
- 3rd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 3.1× to 15.1×
- Peer median
- 8.4×
Biomarin Pharmaceutical's price to sales ratio is 3.3× as of Nov 2, 2026.
That is below its ten-year median of 8.2×, lower than on 97% of days in the last ten years.
Over that time it ranged from 3.1× in May 2026 to 15.1× in Nov 2016.
The median for 10 large drugmakers of a similar size is 8.4×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.3× | 3.1× | 4.0× |
| 2025 | 3.7× | 3.2× | 4.8× |
| 2024 | 4.6× | 4.4× | 7.9× |
| 2023 | 7.9× | 6.5× | 10.9× |
| 2022 | 9.6× | 7.4× | 10.1× |
| 2021 | 8.8× | 7.1× | 9.1× |
| 2020 | 8.5× | 7.1× | 12.8× |
| 2019 | 9.6× | 7.7× | 11.7× |
| 2018 | 9.9× | 9.6× | 13.2× |
| 2017 | 12.5× | 11.5× | 14.8× |
| 2016 | 13.6× | 12.3× | 17.5× |
| 2015 | 18.9× | 16.9× | 29.8× |
| 2014 | 20.2× | 14.4× | 21.7× |
| 2013 | 18.5× | 13.4× | 20.5× |
| 2012 | 12.5× | 8.5× | 12.8× |
| 2011 | 9.0× | 7.0× | 9.4× |
Against its peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| BMRNBiomarin Pharmaceutical | 3.3× |
| TGTXTG Therapeutics | 11.5× |
| PTGXProtagonist Therapeutics | 32.0× |
| JAZZJazz Pharmaceuticals | 3.0× |
| CORTCorcept Therapeutics | 10.5× |
| ALKSAlkermes plc. | 4.5× |
| KNSAKiniksa Pharmaceuticals International | 8.4× |
| AMRXAmneal Pharmaceuticals | 2.1× |
| LGNDLigand Pharmaceuticals | 21.1× |
| INDVIndivior Pharmaceuticals | 3.1× |
| ARQTArcutis Biotherapeutics | 8.5× |
| Peer median | 8.4× |
Where Biomarin Pharmaceutical ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Biomarin Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.